Latterell Venture Partners

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company based in Palo Alto, California, focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004, the company is dedicated to addressing significant unmet medical needs through innovative treatments. Neuraltus is advancing three clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages in conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company is also exploring potential treatments for lysosomal storage disorders like Fabry's disease and Gaucher's disease. Neuraltus leverages a robust technology portfolio and intellectual property established by its founders, who have extensive expertise in medicine and laboratory science.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company based in Palo Alto, California, focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004, the company is dedicated to addressing significant unmet medical needs through innovative treatments. Neuraltus is advancing three clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages in conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company is also exploring potential treatments for lysosomal storage disorders like Fabry's disease and Gaucher's disease. Neuraltus leverages a robust technology portfolio and intellectual property established by its founders, who have extensive expertise in medicine and laboratory science.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company based in Palo Alto, California, focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004, the company is dedicated to addressing significant unmet medical needs through innovative treatments. Neuraltus is advancing three clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages in conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company is also exploring potential treatments for lysosomal storage disorders like Fabry's disease and Gaucher's disease. Neuraltus leverages a robust technology portfolio and intellectual property established by its founders, who have extensive expertise in medicine and laboratory science.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas, established in 2002. The company specializes in creating innovative direct patient care products, particularly focusing on respiratory support. Its flagship offerings include the LifeChoice oxygen concentrators, which are available in both stationary and portable models, designed to provide supplemental oxygen for patients with respiratory illnesses. The LifeChoice products feature a pulse mode system and cater to various oxygen flow needs. Inova Labs also provides essential accessories such as carrying cases, external batteries, and power adapters. The company's products are distributed through authorized providers, who sell them on their respective websites.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Femta Pharmaceuticals is a private company categorized under Pharmaceutical preparations and located in San Diego, CA.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Femta Pharmaceuticals is a private company categorized under Pharmaceutical preparations and located in San Diego, CA.

Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Neuraltus Pharmaceuticals, Inc. is a biopharmaceutical company based in Palo Alto, California, focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004, the company is dedicated to addressing significant unmet medical needs through innovative treatments. Neuraltus is advancing three clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages in conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company is also exploring potential treatments for lysosomal storage disorders like Fabry's disease and Gaucher's disease. Neuraltus leverages a robust technology portfolio and intellectual property established by its founders, who have extensive expertise in medicine and laboratory science.

Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

Proteolix is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting protein degradation pathways to address cancer and autoimmune diseases. The company’s lead product is a pioneering proteasome inhibitor, designed to evaluate safety and efficacy in treating multiple myeloma and various malignancies. In addition to this lead product, Proteolix is advancing a pipeline of novel proteasome inhibitors, which includes an oral formulation and a selective immunoproteasome inhibitor. These therapies aim to provide healthcare professionals with effective treatment options for specific hematologic cancers by inhibiting the cellular proteasome.

Meritage Pharma, Inc. is a company focused on developing prescription products for gastrointestinal and atopic diseases. Founded in 2008 and based in San Diego, California, it specializes in budesonide, a glucocorticoid steroid used in treatments for conditions such as pediatric asthma, allergic rhinitis, and Crohn's disease. The company's primary product candidate is an oral budesonide suspension aimed at treating adolescents and young adults with eosinophilic esophagitis, an allergic inflammation affecting the gastrointestinal tract. Through its innovative approaches, Meritage Pharma seeks to address significant medical needs in these areas.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.

Leptos Biomedical specializes in a proprietary neuromodulation therapy aimed at treating chronic obesity. Established in 2002 and located in Fridley, Minnesota, the company utilizes a pacemaker-like device to electrically activate a specific nerve within the autonomic nervous system, thereby addressing obesity at a neurological level. This innovative approach seeks to offer an alternative treatment option for individuals struggling with weight management.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Evoke Pharma, Inc. is a specialty pharmaceutical company based in Solana Beach, California, focused on developing treatments for gastrointestinal disorders. Founded in 2007, the company is advancing its lead product candidate, Gimoti, an investigational metoclopramide nasal spray designed to relieve symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti aims to offer a novel delivery method through the nasal mucosa, potentially improving the effectiveness of traditional oral therapies for patients suffering from gastrointestinal diseases. Evoke Pharma recognizes the significant unmet medical needs in this field and seeks to provide enhanced treatment options by developing improved formulations of existing drugs. The company has established strategic partnerships with various clinical and regulatory experts to support its product development efforts and plans to continue pursuing collaborations for new acquisitions and asset investments.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Pharmix is a trading company that provides export solutions for food supplements and various pharmaceutical products.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

XTENT is a development stage medical device company focused on creating customizable drug-eluting stent systems for treating coronary artery disease (CAD). These innovative systems allow physicians to tailor both the length and diameter of the stent directly at the site of the diseased artery, known as in-situ customization. By offering this flexibility, XTENT aims to enhance treatment outcomes for patients with CAD, addressing individual anatomical needs more effectively than traditional stents.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Aria Biosystems is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Aria utilizes proprietary bio-layer interferometry (BLI) that enables self-calibration and measurement of molecular interactions using simple-to-use and inexpensive instrumentation. The entire analysis can be completed within minutes and does not require labeling of either probe or target. Aria's analytical capabilities provide greater value in applications where existing methods such as HPLC, ELISA and surface plasmon resonance (SPR) have limitations in throughput, performance and cost.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.